The ABPI welcomes the announcement made by the Chancellor of the Exchequer, George Osborne, of a £600m investment in the UK’s science research infrastructure.


Stephen Whitehead, Chief Executive of the ABPI, said:

"We are pleased the Government has announced a further £600m of investment in the UK’s science research infrastructure. However, whilst it is important that we invest in the research environment, equally important is the commercial environment that UK companies operate in. More could be done to encourage pharmaceutical companies operating here, in particular by ensuring that UK patients benefit from the medicines that result from this research.

"The UK industry supports 67,000 jobs in the UK, contributes £9bn to GDP and has the potential to deliver significant growth to our economy over the coming years. The Government has a huge role to play in ensuring the right environment so that UK patients receive the best medicines and achieve better outcomes as a result, and in turn the nation benefits economically from the success of our industry.

"One year ago the Government launched, the Innovation, Health and Wealth review – a ground breaking plan to ensure that the latest medicines reach patients in a timely manner. We are concerned that while we have made real headway at a national level in implementing IHW, it will take longer to see progress at a local level and therefore we need to maintain the momentum that has been generated over the last year.

"The UK is facing some significant challenges, including being able to establish clinical trials which will benefit patients. Our share of global clinical trials has fallen from six per cent in 2000 to just 1.4 per cent now, whilst NHS spending on the newest medicines is set to shrink as a proportion of health care spending over the next three years. Such barriers mean companies do not know if their newly developed medicines will ever be used in the NHS. This doubt inevitably causes companies to think twice about investing in the UK. Failure to reverse these trends will impact on patient health in the UK, and hamper our efforts to catch up with our European counterparts on health outcomes.”

Media enquiries

ABPI Press Office
Tel: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441
Mobile: +44 (0) 7850 312064 or +44 (0) 7808 641811

Notes to editors

The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.

Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.

The ABPI is recognised by Government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.

Print this page icon Print this page
Please choose the subject of your enquiry from the list below:
Code to enter for submitting the form
Enter the above code here:
Can't read? Try different words.